{"doi":"10.1016/j.contraception.2020.09.001","title":"An implementation project to expand access to self-administered depot medroxyprogesterone acetate (DMPA)","abstract":null,"journal":"Contraception","year":2020,"id":626518,"datarank":0.5050943744979712,"base_score":3.367295829986474,"endowment":3.367295829986474,"self_citation_contribution":0.5050943744979712,"citation_network_contribution":0.0,"self_endowment_contribution":0.5050943744979712,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":28,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1620679,"name":"Rebecca L. Newmark","orcid":"0000-0001-6162-5619","position":1,"is_corresponding":false},{"id":1620680,"name":"Alison Aronstam","orcid":null,"position":2,"is_corresponding":false},{"id":1620681,"name":"Niamh O'Grady","orcid":null,"position":3,"is_corresponding":false},{"id":1620684,"name":"Sara Strome","orcid":null,"position":4,"is_corresponding":false},{"id":1620688,"name":"Sally Rafie","orcid":null,"position":5,"is_corresponding":false},{"id":1103414,"name":"Jennifer Karlin","orcid":"0000-0001-8065-5709","position":6,"is_corresponding":false},{"id":1620678,"name":"Micah Katz","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"An implementation project to expand access to self-administered depot medroxyprogesterone acetate (DMPA)","abstract":"<h4>Objective</h4>To describe the implementation and results of a proactive patient outreach project to offer self-administered, depot medroxyprogesterone (DMPA) subcutaneous (SC) to interested patients at a California safety-net clinic following expanded state Medicaid coverage.<h4>Study design</h4>We contacted non-pregnant patients at an urban, safety-net hospital-based primary care clinic who had been prescribed DMPA intramuscular (IM) in the past year to gauge interest in self-administered DMPA-SC. Interested patients received a prescription for DMPA-SC and a telehealth appointment with a clinic provider to learn self-injection. We recorded patient interest in DMPA-SC, completed appointments, and completed first injections. We conducted initial outreach in May, 2020 and recorded appointment attendance and completed injections through August, 2020.<h4>Results</h4>Of 90 eligible patients (age 17-54), we successfully contacted and discussed DMPA-SC with 70 (78%). Twenty-six (37%) patients expressed interest in DMPA-SC and scheduled telehealth appointments to learn to self-administer the medication. Fifteen (58%) of those interested (21% of the total) successfully self-injected DMPA-SC. Of the 44 (63%) patients not interested in DMPA-SC, the three most common reasons were fear of self-injection (n = 23 [52%]), wanting to stop DMPA (n = 11 [25%]), and satisfaction with DMPA-IM (n = 6 [14%]).<h4>Conclusion</h4>There is interest in and successful initiation of self-administered DMPA-SC among patients at an urban safety net hospital-based primary care clinic who have used DMPA-IM in the last year.<h4>Implications</h4>Our data provide evidence for the interest and successful first injection rate after offering self-administered DMPA-SC to patients on DMPA-IM. Expanding coverage of self-administered DMPA-SC could increase patient-centeredness and accessibility of contraception as well as reduce patient anxiety around COVID-19 transmission without losing contraceptive access.","is_dataset_classified":null,"base_score":3.367295829986474,"endowment":3.367295829986474,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"32931811","pmcid":"PMC7486600","openalex_id":"https://openalex.org/W3085685474","authors":[],"funders":[{"funder_name":"National Institute of General Medical Sciences","grant_id":"T32GM007618","title":null}],"total_grants":1,"fwci":3.2505,"citation_percentile":0.93002987,"influential_citations":2,"citation_trend":[{"year":2020,"count":1},{"year":2021,"count":8},{"year":2022,"count":5},{"year":2023,"count":5},{"year":2024,"count":4},{"year":2025,"count":3},{"year":2026,"count":2}],"oa_status":"green","license":"https://www.elsevier.com/legal/tdmrep-license","oa_locations":[{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7486600","host_type":"repository"},{"url":"https://escholarship.org/content/qt4xm0t3xj/qt4xm0t3xj.pdf?t=qmgowi","host_type":"GREEN"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7486600","host_type":"repository"},{"url":"https://api.elsevier.com/content/article/PII:S0010782420303413?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0010782420303413?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.contraception.2020.09.001","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/32931811","host_type":"repository"},{"url":"https://escholarship.org/uc/item/4xm0t3xj","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC7486600","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC7486600?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Reproductive Health and Contraception","Reproductive tract infections research","Antibiotic Use and Resistance","Medicine"],"mesh_terms":["Contraceptive Agents, Hormonal","Hormonal Contraception","COVID-19","Adolescent","Adult","California","Female","Humans","Injections, Subcutaneous","Medicaid","Middle Aged","Patient Acceptance of Health Care","Primary Health Care","Self Administration","United States","Telemedicine","Medroxyprogesterone Acetate","Young Adult","Safety-net Providers"],"keywords":["Medroxyprogesterone acetate","Depot","Medicine","Medroxyprogesterone","Gynecology","Obstetrics","Internal medicine","Estrogen","Injectable Contraception","Contraceptive Access","Reproductive Autonomy","Depomedroxyprogesterone Acetate","Covid-19 Response"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-04T14:12:33.042301Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}